Company Analysis WuXi Biologics (Cayman) Inc.
1. Summary
Advantages
- Price (3.7 $) is less than fair price (4.92 $)
- The stock's return over the last year (113.26%) is higher than the sector average (-10.48%).
- Current debt level 4.07% is below 100% and has decreased over 5 years from 10.95%.
Disadvantages
- Dividends (0%) are below the sector average (1.53%).
- The company's current efficiency (ROE=8.43%) is lower than the sector average (ROE=13.38%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| WuXi Biologics (Cayman) Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -10.9% | -1.2% |
| 90 days | 70.5% | -6.4% | -6.6% |
| 1 year | 113.3% | -10.5% | 6.9% |
WXIBF vs Sector: WuXi Biologics (Cayman) Inc. has outperformed the "Healthcare" sector by 123.74% over the past year.
WXIBF vs Market: WuXi Biologics (Cayman) Inc. has outperformed the market by 106.34% over the past year.
Slightly volatile price: WXIBF is more volatile than the rest of the market on "OTC" over the last 3 months, with typical deviations of about +/- 5-15% per week.
Long period: WXIBF with weekly volatility of 2.18% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (3.7 $) is lower than the fair price (4.92 $).
Price significantly below the fair price: The current price (3.7 $) is 33% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (35.18) is higher than that of the sector as a whole (31.32).
P/E vs Market: The company's P/E (35.18) is lower than that of the market as a whole (53.47).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.72) is lower than that of the sector as a whole (3.11).
P/BV vs Market: The company's P/BV (2.72) is higher than that of the market as a whole (-8.35).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (7.02) is higher than that of the sector as a whole (3.24).
P/S vs Market: The company's P/S indicator (7.02) is higher than that of the market as a whole (4.74).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (20.07) is higher than that of the sector as a whole (10.15).
EV/Ebitda vs Market: The company's EV/Ebitda (20.07) is lower than that of the market as a whole (28.31).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 20.26% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (20.26%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-29.36%).
5.4. ROE
ROE vs Sector: The company's ROE (8.43%) is lower than that of the sector as a whole (13.38%).
ROE vs Market: The company's ROE (8.43%) is higher than that of the market as a whole (4.9%).
5.5. ROA
ROA vs Sector: The company's ROA (6.01%) is lower than that of the sector as a whole (6.25%).
ROA vs Market: The company's ROA (6.01%) is lower than that of the market as a whole (16.49%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (11.15%) is lower than that of the sector as a whole (15.56%).
ROIC vs Market: The company's ROIC (11.15%) is higher than that of the market as a whole (11.06%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.53%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
